摘要
目的:对补肾化瘀法联合沙利度胺治疗多发性骨髓瘤的临床疗效进行评价。方法:将120例多发性骨髓瘤患者分为2组进行对比治疗,其中对照组采用VAD方案,治疗组才对照组的基础上使用补肾化瘀法联合沙利度胺治疗。结果:经过治疗后,治疗组的患者总有效率达到75%,对照组的患者总有效率达到60%。2组有效率比较差异有统计学意义(P<0.05);在M蛋白、骨髓浆细胞、成骨细胞和破骨细胞等各项指标上,2组与治疗前相比均有明显下降,而治疗组下降较对照组更为明显(P<0.05),在肾功能、生活治疗和不良反应评估上,治疗组患者较对照组患者所受化疗的影响更小。结论:补肾化瘀法联合沙利度胺治疗多发性骨髓瘤的临床疗效更为显著,并且具有不良反应较少和治疗后患者的生活质量较高的优点,具有较大的临床应用价值,值得进行推广。
Objective：To evaluate the efficacy of Kidney Tonifying and Stasis Removing Method with Thalidomide in treatment of multiple myeloma.Methods：A total of 120 patients with multiple myeloma were divided into two groups.The control group received VAD treatment,the observation group received Kidney Tonifying and Stasis Removing Method on the basis of the control group.Results：After treatment,the total effective rate of observation group was 75%,significantly better than the control group＇s 60%.As for the indicators such as M protein,bone marrow plasma cells,osteoblasts and osteoclasts,the two groups met significantly drop but the observation group had significantly better results compared with the control group （P 〈 0.05）.On renal function,life quality and side effects,the observation group had less negative effects than the control group.Conclusion：The efficacy of Kidney Tonifying and Stasis Removing Method with Thalidomide in treatment of multiple myeloma is clear,and with fewer side effects and better quality of life after treatment,which has great clinical value,and is worthy of clinical promotion.
出处
《世界中医药》
CAS
2017年第1期104-108,共5页
World Chinese Medicine
基金
河北省卫生厅资助基金(编号:hb28123)
关键词
补肾化瘀法
沙利度胺
多发性骨髓瘤
VOA方案
临床疗效
Kidney Tonifying and Stasis Removing Method
Thalidomide
Multiple myeloma
VOA programs
Clinical efficacy
